Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in kidney transplant recipients with diabetes mellitus

Diabet Med. 2024 Aug;41(8):e15383. doi: 10.1111/dme.15383. Epub 2024 Jun 10.

Authors

SophieAnne Buckley¹, Yuvanaa Subramaniam^{1

2}, Ritwika Mallik^{1

3}, Dorcas Mukuba¹, Mahalia Casabar⁴, Omer Ali⁴, Connor Byrne⁴, Tahseen A Chowdhury¹

Affiliations

¹ Department of Diabetes and Metabolism, The Royal London Hospital, London, UK.
² Department of Diabetes and Metabolism, Guy's and St Thomas' NHS Foundation Trust, London, UK.
³ Centre for Obesity Research, University College, London, UK.
⁴ Department of Nephrology, The Royal London Hospital, London, UK.

PMID: 38859632
DOI: 10.1111/dme.15383

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Benzhydryl Compounds / adverse effects
Benzhydryl Compounds / therapeutic use
Diabetes Mellitus, Type 2* / drug therapy
Diabetic Nephropathies
Female
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use
Kidney Transplantation*
Male
Middle Aged
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Transplant Recipients
Treatment Outcome

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents
Benzhydryl Compounds